



IAEM Clinical Guideline

Henoch Schonlein Purpura

Version 1

March 2018

Author: Dr Tom Brennan

Guideline lead: Dr Carol Blackburn, in collaboration with IAEM Guideline Development Committee and Joint Clinical Guidelines committee of the Children's hospitals (Our Lady's Children Hospital Crumlin, Children's University Hospital Temple St. and Tallaght Children's Hospital).

DISCLAIMER

IAEM recognises that patients, their situations, Emergency Departments and staff all vary. These guidelines cannot cover all clinical scenarios. The ultimate responsibility for the interpretation and application of these guidelines, the use of current information and a patient's overall care and wellbeing resides with the treating clinician.

GLOSSARY OF TERMS

BP	Blood pressure
CNS	Central nervous system
FBC	Full blood count
HSP	Henoch Schonlein Purpura
NSAID	Non-steroidal anti-inflammatory drug
RCT	Randomised controlled trial
URTI	Upper respiratory tract infection

Henoch Schonlein Purpura

INTRODUCTION

Henoch-Schönlein Purpura (HSP) is the commonest small vessel vasculitis of childhood with an estimated incidence of 14–20.4/100 000. The vasculitis (IgA-dominant immune deposits) affects small vessels and typically involves skin, gut and glomeruli and is associated with arthralgias or arthritis.

HSP typically presents with the triad of:

- Palpable purpuric rash on the extensor surfaces of limbs (mainly lower) and buttocks,
- Joint pain/swelling in areas involved by rash, and
- Abdominal pain.

Abdominal pain or arthralgia sometimes may precede the rash. The cause is unknown but there may be a recent history of an upper respiratory tract infection.

PARAMETERS

Target audience: This guideline is intended for Emergency Department and medical staff.

Patient population: Commonest age group is 2-8yrs old but guideline suitable for use in children up to 16 yrs old.

Exclusion criteria: Patient groups specifically excluded from guideline are: patients with platelet function disorders / low platelet counts, patients with signs of evolving sepsis.

AIM

The aim of the guideline is to provide guidance to safely diagnose and initiate management of HSP, and to provide a follow up plan for patients.

DEFINITION OF TERMS

Purpura – bleeding under the skin or into mucosal membranes. Purpuric lesions can be subdivided based on size into

- Petechiae (<3mm)
- Purpura (3-10mm)
- Eccymosis (>10mm)

Purpuric lesions in HSP are typically palpable.

ASSESSMENT

Patient History

Often there is a history of a preceding viral URTI. Presentation is commonest in spring/autumn. Group A Strep may be a trigger.

Physical Examination

- Purpura: Usually symmetrical, affecting lower limbs or buttocks first but may affect other parts of body (less commonly). Typically palpable in HSP.
- Joint Pain: Swelling and arthralgia of large joints are often the patient's main complaint. In most situations this pain resolves spontaneously within 24-48 hours.
- Abdominal pain: Uncomplicated abdominal pain often resolves spontaneously within 72 hours. However serious abdominal complications may occur including

intussusception (usually ileo-ileal), bloody stools, haematemesis, spontaneous bowel perforation, and pancreatitis.

- Renal disease: Renal involvement affects 60-70% of patients. Haematuria is present in up to 90%, but only 5% are persistent or recurrent. Less common renal manifestations include proteinuria, nephrotic syndrome, isolated hypertension, renal insufficiency and renal failure (<1%). Renal involvement may only present during the convalescent period. Ureteric mucosal lesions are rarely seen but can cause renal colic and degree of ureteric obstruction.
- Subcutaneous oedema (scrotum, scalp, hands, feet, sacrum): This can be very painful.
- Rare complications - pulmonary and CNS involvement.

MANAGEMENT

Investigations

Perform BP, urinalysis, check FBC and renal and liver function (including albumin).

Acute management

- Discuss with nephrologist if:
 - Hypertension
 - Abnormal renal function
 - Nephrotic syndrome (oedema, low albumin, proteinuria)
 - Acute nephritis (Haematuria, proteinuria, oedema, hypertension, oliguria)

- Surgical referral if abdominal/ testicular pain is dominant at presentation.
- Analgesia for joint pain (check degree of renal involvement before deciding on NSAID use).
- Consider admission for bed rest if there is significant joint swelling / pain.
- Steroids at a dose of 1mg per kg may be considered for patients who have predominant joint or abdominal pain at presentation - if you are considering commencing steroids, consider admission.

Steroids are no longer routinely recommended for HSP (RCT Dudley et al 2013).

- Hypertension in the absence of renal involvement suggests CNS vasculitis and needs urgent assessment.

On-going management

- Weekly BP and urine dipstick (early am urine) check for 1 month at GP.
- BP and urine check, then each 4 to 6 weeks for 6 months (GP also appropriate for this follow up).
- Some sources recommend yearly BP and urine check for life where there has been significant renal involvement at outset.
- Nephrology referral if:
 - Hypertension
 - Persistent frank haematuria
 - Persistent/worsening proteinuria for >1 month

Follow up / Review

- The required frequency of follow up review has not been defined.
- Follow up monthly for 6 months is reasonable as renal disease can present late, but is unlikely to develop after 6 months.
- Follow up checks may be performed by the family doctor in the absence of problems at presentation such as significant renal involvement (i.e. more than mild transient haematuria).
- Should symptoms evolve or should the patient develop renal involvement the GP should have a clear referral plan for the patient. This may be to the local paediatric ED to facilitate referral to renal services.

SPECIAL CONSIDERATIONS

Recurrence

Rarely a recurrent form of HSP may occur. Patients typically present with recurrent purpuric rash a few months to greater than a year after the initial episode. The lower limbs are usually affected. Such patients require BP and urine check and careful consideration of differentials including meningococcal disease. There are no clinical or lab markers indicative of the likelihood of recurrent disease. Annual follow up review is suggested.

Renal disease

Long-term prognosis is determined predominantly by the extent of renal involvement. Severe early renal involvement is more likely to be associated with a poor outcome.

COMPANION DOCUMENTS

- [GP Proforma Letter](#)
- [Parent Information Leaflet](#)
- [Evidentiary table](#)